12.08
2.11%
0.25
시간 외 거래:
12.04
-0.04
-0.33%
전일 마감가:
$11.83
열려 있는:
$11.9
하루 거래량:
4.65M
Relative Volume:
1.03
시가총액:
$8.79B
수익:
$125.68M
순이익/손실:
$4.81B
주가수익비율:
-9.0149
EPS:
-1.34
순현금흐름:
$-781.21M
1주 성능:
+0.67%
1개월 성능:
-3.21%
6개월 성능:
+14.39%
1년 성능:
+6.43%
Roivant Sciences Ltd Stock (ROIV) Company Profile
명칭
Roivant Sciences Ltd
전화
441-295-5950
주소
CLARENDON HOUSE, 2 CHURCH STREET, HAMILTON HM11
ROIV을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
ROIV
Roivant Sciences Ltd
|
12.08 | 8.79B | 125.68M | 4.81B | -781.21M | 5.65 |
VRTX
Vertex Pharmaceuticals Inc
|
405.76 | 104.50B | 10.63B | -479.80M | -1.35B | -1.99 |
REGN
Regeneron Pharmaceuticals Inc
|
715.19 | 78.59B | 13.85B | 4.65B | 3.32B | 40.41 |
ARGX
Argen X Se Adr
|
620.16 | 37.08B | 1.86B | -40.29M | -1.28B | -0.85 |
ALNY
Alnylam Pharmaceuticals Inc
|
233.62 | 30.13B | 2.09B | -332.26M | 16.06M | -2.62 |
BNTX
Biontech Se Adr
|
115.30 | 27.64B | 3.30B | -501.07M | 1.03B | -2.1146 |
Roivant Sciences Ltd Stock (ROIV) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-02-15 | 개시 | Wolfe Research | Outperform |
2024-01-05 | 개시 | Piper Sandler | Overweight |
2023-12-12 | 개시 | Deutsche Bank | Buy |
2023-10-17 | 개시 | Guggenheim | Buy |
2023-06-08 | 개시 | BofA Securities | Neutral |
2022-10-27 | 개시 | JP Morgan | Overweight |
2022-05-23 | 개시 | SVB Leerink | Outperform |
2022-04-29 | 개시 | Cantor Fitzgerald | Overweight |
2021-12-15 | 개시 | Goldman | Buy |
2021-11-08 | 개시 | H.C. Wainwright | Buy |
2021-10-28 | 개시 | Citigroup | Buy |
2021-10-26 | 개시 | Cowen | Outperform |
2021-10-26 | 개시 | Jefferies | Buy |
2021-10-26 | 개시 | Truist | Buy |
모두보기
Roivant Sciences Ltd 주식(ROIV)의 최신 뉴스
Why Roivant Sciences Ltd. (ROIV) Is Skyrocketing - Insider Monkey
10 Firms End 2024 Stronger With Impressive Gains - Insider Monkey
Strategic Sale: Eric Venker Decides To Exercise Options Worth $3.86M At Roivant Sciences - Benzinga
Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells $2,050,704.16 in Stock - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) COO Sells 176,900 Shares of Stock - MarketBeat
Roivant Sciences' president sells common shares worth $4.1 million - Investing.com
Principal Financial Group Inc. Has $11.65 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant sciences president Eric Venker sells $1.15 million in shares By Investing.com - Investing.com Australia
Eric Venker Sells 100,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Insider Selling: Roivant Sciences Ltd. (NASDAQ:ROIV) CIO Sells 689,495 Shares of Stock - MarketBeat
Mayukh Sukhatme Sells 185,946 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant Sciences’ CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com Nigeria
Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares By Investing.com - Investing.com South Africa
Roivant Sciences' CIO Mayukh Sukhatme sells $10.6m in shares - Investing.com India
Roivant sciences president Eric Venker sells $1.15 million in shares - Investing.com
Barclays PLC Buys 75,609 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Mayukh Sukhatme Sells 412,584 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) Stock - MarketBeat
Roivant sciences executive sells common shares worth $4.97 million - Investing.com India
Geode Capital Management LLC Acquires 1,460,205 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Retirement Systems of Alabama Buys 112,286 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Ramaswamy Urges BuzzFeed to Cut Jobs, Air More Conservative Voices - MSN
Trump administration will have financial ties to biotechs - BioCentury
State Street Corp Buys 1,118,561 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd. (NASDAQ:ROIV) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
What is Leerink Partnrs' Estimate for ROIV Q3 Earnings? - MarketBeat
Several Positive Developments Lifted Roivant (ROIV) in Q3 - Insider Monkey
Edgestream Partners L.P. Buys Shares of 48,226 Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 762,953 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
MetLife Investment Management LLC Has $2.60 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant to stop lung disease drug development after trial failure - MSN
Roivant Sciences: A Biotech Growth Play With Major Ambitions (NASDAQ:ROIV) - Seeking Alpha
Roivant Sciences Ltd. (NASDAQ:ROIV) Holdings Cut by Melqart Asset Management UK Ltd - MarketBeat
Maven Securities LTD Purchases Shares of 400,000 Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Charles Schwab Investment Management Inc. Buys 646,627 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Phase II miss for namilumab - The Pharma Letter
Erste Asset Management GmbH Buys New Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ends Namilumab Study Due to Inefficacy - TipRanks
Roivant falls as lung disease drug fails in mid-stage study - XM
TOMS Capital Investment Management LP Invests $46.33 Million in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Thrivent Financial for Lutherans Sells 62,228 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Fmr LLC Increases Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Rubric Capital Management LP Sells 600,000 Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Loomis Sayles & Co. L P Has $45.15 Million Stock Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences president Eric Venker sells $1.13 million in shares By Investing.com - Investing.com Nigeria
Roivant Sciences president Eric Venker sells $1.13 million in shares - Investing.com
Thompson Siegel & Walmsley LLC Takes $5.93 Million Position in Roivant Sciences Ltd. (NASDAQ:ROIV) - MarketBeat
Roivant Sciences Ltd (ROIV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):